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Adenosine has been shown to affect both sinus node 
automaticity and atrioventricular (AV) nodal conduc-
tion. The effects of increasing doses of intravenous aden-
osine were assessed in 46 patients with supraventricular 
tachyarrhythmias. Adenosine reliably terminated epi-
sodes of supraventricular tachycardia in all 16 patients 
with A V reciprocating tachycardia, in 13 of 13 patients 
with A V nodal reentrant tachycardia and in I of 2 pa-
tients with junctional tachycardia with long RP inter-
vals. Adenosine produced transient high grade A V block 
without any effect on atrial activity in six patients with 
intraatrial reentrant tachycardia, four patients with atrial 
flutter, three patients with atrial fibrillation and in single 
Since the report by Drury and Szent-Gyorgyi (I) in 1929, 
adenosine and several adenine nucleotides have been known 
to affect the electrophysiologic properties of cardiac tissue. 
These effects include depression of sinus node automaticity 
and atrioventricular (A V) nodal conduction, shortening and 
hyperpolarization of the atrial action potential, decreased 
automaticity in Purkinje fibers and antagonism of the effects 
of isoproterenol on the action potential of ventricular myo-
cytes. These actions of adenosine are thought to be me-
diated directly by the effect of the nucleoside on potassium 
and calcium conductance as well as indirectly by antagonism 
of the electrophysiologic actions of intracellular cyclic aden-
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patients with either sinus node reentry or an automatic 
atrial tachycardia. The dose of adenosine required to 
terminate episodes of supraventricular tachycardia was 
variable (range 2 to 23 mg). Side effects were minor and 
of short duration. 
These results demonstrate that adenosine is useful for 
the acute therapy of supraventricular tachycardia when-
ever reentry through the A V node is involved. When 
arrhythmia termination is not affected, atrial activity 
may be more readily analyzed during adenosine-induced 
transient A V block. 
(J Am Coll Cardiol 1985;6:417-25) 
osine-3' 5' -monophosphate (2-6). Recently, we reported (7) 
that adenosine depressed sinus node automaticity and A V 
nodal conduction after intravenous administration in hu-
mans. Because adenosine is cleared from the circulation by 
cellular uptake and metabolism within seconds after intra-
venous injection (8), we postulated that its ability to tran-
siently depress A V nodal conduction might enable it to be 
used for the rapid termination or diagnosis, or both, of 
supraventricular tachyarrhythmias. This might be of benefit 
in several situations. The very short duration of action of 
adenosine is of potential benefit in the electrophysiology 
laboratory because the drug can be administered repetitively 
without persistent effects that might influence the subse-
quent course of the study. In the acute clinical setting, the 
rapid clearance of adenosine from plasma permits the nu-
cleoside to be administered without concern for long-lasting 
or cumulative adverse reactions. 
In an earlier report (7), we described the electrophysi-
ologic effects of adenosine in patients undergoing electro-
physiologic studies, including some preliminary observa-
tions in six patients with supraventricular tachycardia. Our 
current study describes our observations on the effects of 
intravenous adenosine in 46 patients with supraventricular 
arrhythmias studied to date. These data allow a more com-
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plete characterization of the dose-response relation of aden-
osine, its site of action, its potential for toxicity and the 
spectrum of responses when it is administered to patients 
with supraventricular tachyarrhythmias. 
Methods 
Study patients. The study group included 46 patients 
(26 male and 20 female) ranging in age from 10 to 85 years. 
Pertinent clinical characteristics are listed in Table I. Pa-
tients were studied while undergoing electrophysiologic study 
(35 patients), during a spontaneous episode of clinical tachy-
cardia in the emergency room or their hospital room (9 
patients) or in both settings on separate occasions (2 patients). 
Electrophysiologic studies. Electrophysiologic studies 
were performed with the patient in the fasting, non sedated 
state after informed consent had been obtained. Four 6F 
quadripolar electrode catheters (USCI) with a 0.5 or 1.0 cm 
interelectrode distance were introduced by way of the fem-
oral. antecubital, subclavian or internal jugular vein and 
advanced to the heart under fluoroscopic guidance. The 
catheters were positioned in the high right atrium, across 
the A V valve in a position that permitted reliable recording 
of the His bundle potential, and in the right ventricular apex. 
Left atrial activity was recorded with an electrode catheter 
that was placed either in the coronary sinus or in the left 
atrium by way of a patent foramen ovale. Intracardiac elec-
trograms were filtered at less than 30 and greater than 500 
Hz and were displayed simultaneously with scalar electro-
cardiographic leads I, II and V I on a multichannel oscil-
loscope (Electronics for Medicine, VR-16). Signals were 
stored on frequency-modulated magnetic tape (Honeywell 
model 101) and recordings reproduced for analysis on an 
ink-jet recorder (Mingograf-16, Siemens Medical Products). 
Programmed cardiac stimulation was performed using a pro-
grammable constant current stimulator (Medtronic 5325 or 
Bloom DTU-IOI) that delivered rectangular pulses 2 ms in 
duration at four times diastolic threshold. 
The protocol for atrial and ventricular stimulation has 
been previously described (9). Arrhythmia mechanisms were 
determined on the basis of local electrogram activation pat-
terns and responses to stimulation according to standard 
criteria (10). 
Systemic blood pressure was continuously monitored 
throughout the study using an intraarterial cannula placed 
in a radial or femoral artery and connected to a Statham 
P23-ID pressure transducer (Gould Medical Products). 
Patients studied in other settings. Eleven patients with 
supraventricular arrhythmias who were seen in the emer-
gency room as outpatients or in the hospital were invited to 
participate in the trial. In each case, a 12 lead electrocar-
diogram and a medication history were obtained. Carotid 
sinus massage was performed before adenosine administra-
tion in all patients, but this did not result in arrhythmia 
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termination or increased A V block. Arrhythmia mechanisms 
were tentatively classified by surface electrocardiographic 
criteria, by data obtained at a prior or subsequent electro-
physiologic study or by analysis of atrial activity in tachy-
cardia during adenosine-induced A V block (10). Adenosine 
was then administered intravenously. 
Adenosine administration. Crystalline adenosine (Sigma 
Chemical Co.) was dissolved in normal saline solution in a 
concentration of 5 or 10 mg/ml. The solution was prepared 
under sterile conditions. Adenosine concentrations in the 
injectate were confirmed by high pressure liquid chroma-
tography (II). 
In all patients, adenosine was injected rapidly into a 
peripheral intravenous catheter and flushed in with 10 ml 
of saline solution. Pilot experiments had indicated that the 
speed and the site (central versus peripheral) of injection 
markedly influenced individual responsiveness to a given 
dose of adenosine. This finding is consistent with the fact 
that adenosine is cleared from the circulation by uptake and 
metabolism by cellular elements of blood and vascular en-
dothelium with a half-time of less than 10 seconds (8). The 
initial injection used was 37.5 /Lg/kg. If no effect was ob-
served within 60 seconds, a second injection of 75 /Lg/kg 
was administered. This process of increasing the dose with 
equal 37.5 /Lg/kg increments (37.5,75, 112.5, and so on) 
was continued until either tachycardia termination or A V 
block was observed. In one patient, there was no electro-
physiologic effect after injection of adenosine at any dose 
up to 450 /Lg/kg, and higher doses were not administered. 
This patient had been receiving theophylline for chronic 
obstructive pulmonary disease and her theophylline serum 
concentration was 19.4 /Lg/ml (1 x 10- 4 M). This con-
centration of theophylline will block the electrophysiologic 
effects of adenosine in the isolated heart (12). In each patient 
studied in the electrophysiology laboratory, adenosine was 
administered during at least 2 (range 2 to 15) episodes of 
tachycardia. Patients studied outside the electrophysiologic 
laboratory received adenosine only once if arrhythmia ter-
mination occurred. In selected patients, adenosine was also 
administered during either sinus rhythm or atrial or ven-
tricular pacing and its effects on A V conduction were also 
assessed. 
All procedures in this study were approved by and con-
formed to the guidelines of the Human Investigations Com-
mittee of the University of Virginia. 
Results 
A V reciprocating tachycardia. Sixteen patients had an 
accessory A V pathway with orthodromic reciprocating 
tachycardia. Of these 16 patients, 8 (Cases 39 to 46) dem-
onstrated preexcitation either during sinus rhythm or with 
atrial stimulation. The remaining eight (Cases 24 to 31) had 
a concealed bypass tract that demonstrated only retrograde 
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Table 1. Patient Characteristics 
Age (yr) Arrhythmia 
Case & Sex Mechanism 
I SSM AAT 
2 55F AF 
3 SSM AF 
4 66F AF 
5 51M AFI 
6 73F AFi 
7 17M AFi 
884M AFI 
9 72F JTLRP 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
10F 
69M 
73M 
82M 
42F 
68M 
38F 
61M 
70F 
56F 
51F 
59M 
82F 
60M 
25F 
72M 
85F 
70F 
59M 
67F 
59M 
SSM 
75M 
41M 
64M 
31M 
70F 
47M 
55F 
34M 
16M 
31F 
48M 
61M 
17F 
34F 
38F 
JTLRP 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVNRT 
AVRT-CBT 
AVRT-CBT 
AVRT-CBT 
AVRT-CBT 
AVRT-CBT 
AVRT-CBT 
AVRT-CBT 
AVRT-CBT 
JART 
JART 
JART 
JART 
JART 
JART 
SN!U 
AVRT-WPW 
AVRT-WPW 
AVRT-WPW 
AVRT-WPW 
AVRT-WPW 
AVRT-WPW 
AVRT-WPW 
AVRT-WPW 
Atrial Effect of 
CL Adenosine 
420 AV block 
AV block 
AV block 
AV block 
190 AV block 
230 AV block 
260 AV block 
ZOO AV block 
300 None 
335 Termination 
330 Termination 
360 Termination 
360 Termination 
380 Termination 
450 Termination 
270 Termination 
445 Termination 
400 Termination 
320 Termination 
400 Termination 
400 Termination 
370 Termination 
500 Termination 
335 Termination 
350 Termination 
500 Termination 
420 Termination 
350 Termination 
350 Termination 
340 Termination 
310 Termination 
305 AV block 
340 AV block 
310 AV block 
260 AV block 
380 AV block 
310 AV block 
400 AV block 
380 Termination 
470 Termination 
370 Termination 
260 Termination 
360 Termination 
340 Termination 
280 Termination 
410 Termination 
Dose 
(J-Lg/kg) 
37.5 
225 
112.5 
75 
187.5 
112.5 
75 
75 
450 
150 
187.5 
75 
75 
37.5 
187.5 
75 
75 
37.5 
75 or 112.5 
75 
37.5 
37.5 
37.5 
ISO 
75 
75 
75 
287.5 
37.5 or 75 
75 or 112.5 
75 
112.5 
37.5 or 75 
225 
187.5 
112.5 
112.5 
37.5 
37.5 or 75 
37.5 
75 
75 
112.5 or ISO 
37.5 
112.5 or ISO 
75 
Dose 
(mg) 
3.3 
20.6 
14.6 
4.3 
15.6 
8.7 
5.0 
6.2 
19.0 
4.2 
11.5 
5.0 
6.0 
2.5 
13.1 
3.3 
8.2 
3.4 
4.7 or 7 
5 
3.2 
4.9 
4.4 
12.8 
3.1 
4.4 
5 
23 
2.8 or 5.6 
5.8 or 8.7 
6.4 
7.5 
3.3 or 6.6 
25 
8.5 
7.5 
7.2 
3.4 
3.5 or 7 
2.5 
15.9 
7.2 
7.9 or 10.5 
2 
5.1 or 6.8 
4.8 
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Time (seconds) Adverse 
to Effect Reaction 
6 
15 Flush 
10 
15 
21 
26 Dyspnea 
15 
25 
17 
26 
12 
23 
22 
29 
12 
17 
24 
IS 
24 
20 
18 
9 
Dyspnea 
Flush 
Flush 
Dyspnea 
Flush, dyspnea 
Flush 
Other 
Therapy 
Dig, Ver 
Dig 
Dig 
Dig 
Dig, Quin 
Big, Quin 
Theophylline 
Dig 
Dig 
419 
IS 
33 
21 
22 
25 
23 
19 
25 
18 
14 
24 
30 
23 
18 
24 
21 
24 
20 
21 
20 
14 
21 
22 
Dig, Ver, Prop 
Dyspnea 
Flush 
Dyspnea 
Flush 
Dyspnea 
Dyspnea 
Dyspnea 
Dig, Amio 
Dig 
Quin 
Ver, Diso 
AA T = automatic atrial tachycardia; AF = atrial fibrillation; AFi = atrial flutter; Amio = amiodarone; A V = atrioventricular; A VNRT = A V 
nodal reentrant tachycardia; AVRT-CBT = AV reciprocating tachycardia with concealed bypass tract; CL = cycle length; Dig = digoxin; Diso = 
disopyramide; F = female; JART = intraatrial reentrant tachycardia; JTLRP = junctional tachycardia with a long RP interval; M = male; Prop = 
propranolol; Quin = quinidine; SNRT = sinus node reentrant tachycardia; Ver = verapamil; WPW = Wolff-Parkinson-White syndrome. 
ventriculoatrial (VA) conduction. The tachycardia cycle 
lengths during supraventricular tachycardia ranged from 260 
to 500 ms (358 ± 33, mean ± SO). Adenosine at a dose 
of 91 ± 52 J-Lg/kg terminated every episode of supraven-
tricular tachycardia. A characteristic pattern of response was 
observed in each patient (Fig. 1). The tachycardia cycle 
length remained constant immediately after injection of 
adenosine. Ten to 30 seconds after injection, there was a 
slight lengthening of the tachycardia cycle length and a slight 
increase in the arterial blood pressure. The tachycardia would 
then terminate and the arterial pressure would return to 
normal with resumption of sinus rhythm. The actual doses 
420 
IT 
100-
RAP 
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Figure 1. Case 42. Tennination of AV 
reciprocating tachycardia with intra-
venous adenosine. The recordings were 
obtained during electrophysiologic 
study in a patient who had a left-sided 
accessory pathway. The tracings begin 
18 seconds after adenosine injection 
and represent, from top to bottom, 
surface electrocardiographic lead II, 
intracardiac recordings from the right 
atrium (RA), coronary sinus (CS), 
bundle of His (HB) and right ventricle 
(R V) and a radial artery pressure (RAP) 
recording. The tachycardia tenninates 
with block in the A V node 22 seconds 
after adenosine injection. Note the im-
provement in arterial pressure asso-
ciated with arrhythmia tennination. LA 
= left atrium; LV = left ventricle. 
0-
required for termination of the supraventricular tachycardia 
ranged from 2 to 23 mg (6 ± 4). Tachycardia termination 
occurred 21.5 ± 3 seconds after injection of adenosine. In 
all cases the reentrant circuit was broken by block during 
anterograde conduction through the A V node. 
We also observed that adenosine could be used to test 
for the presence of preexcitation in patients with atypical 
manifestations of preexcitation or with only intermittent 
preexcitation on the surface electrocardiogram. In such pa-
tients, atrial pacing was continued during adenosine admin-
istration to eliminate the negative chronotropic effects of 
adenosine on the sinus node. After adenosine injection, 
preexcitation became more readily apparent as the contri-
bution to ventricular activation from conduction over the 
A V node and His-Purkinje system was eliminated. No change 
in the interval between the stimulus and the onset of the 
delta wave during atrial pacing or in the A V interval during 
ventricular pacing was noted in the patients in this series 
with an accessory pathway. 
A V nodal reentrant tachycardia. Thirteen patients 
(Cases 11 to 23) had A V nodal reentrant tachycardia in-
volving anterograde conduction over a slow pathway and 
retrograde conduction over a fast pathway. As in the patients 
with A V reciprocating tachycardia, adenosine at a dose of 
80 ± 47 p.g/kg (5.8 ± 2.9 mg) uniformly terminated every 
episode of tachycardia. The time between injection and ter-
mination was also similar (19 ± 6 seconds) in both groups 
of patients. Intracardiac recordings showed that the block 
that terminated the arrhythmia could occur either during 
anterograde slow (5 patients), retrograde fast (2 patients) or 
either slow or fast (2 patients) pathway conduction (Fig. 2). 
Junctional tachycardia with long RP intervals. Two 
patients (Cases 9 and 10) with junctional tachycardia with 
long RP intervals were studied. In one patient, two separate 
Figure 2. Case 9. Effect of aden-
osine on A V nodal reentrant tachy-
cardia (AVNRT). The tracings be-
gin 11 seconds after injection of 
adenosine (75 p,g/kg). The lack of 
atrial activation after the last ven-
tricular beat of the tachycardia in-
dicates that the tachycardia is ter-
minated by block during retrograde 
conduction. Note the prompt re-
sumption of sinus rhythm after the 
tachycardia was broken. A V nodal 
reentrant tachycardia was observed 
to tenninate during either antero-
grade or retrograde conduction in 
this series. HRA = high right 
atrium; NSR = nonnal sinus 
rhythm; PVC = premature ven-
tricular complex; other abbrevia-
tions as in Figure 1. Time lines are 
at 100 ms intervals. 
JACC Vol. 6, No, 2 
August 1985:417-25 
II 
DIMARCO ET AL. 421 
ADENOSINE IN ATRIAL ARRHYTHMIAS 
Figure 3. Case 10, Effect of adenosine 
on junctional tachycardia with a long RP 
interval, The tracings were obtained dur-
ing electrophysiologic study and are la-
beled as in Figures I and 2, They begin 
14 seconds after adenosine injection, The 
tachycardia is seen to terminate with block 
during retrograde conduction, Note that 
the second and fourth beats after tachy-
cardia termination are echo beats, In this 
patient with an incessant tachycardia, the 
tachycardia resumed within seconds after 
these tracings. This was not observed in 
patients without incessant arrhythmias. 
A A RA~~~~~~----~~~~~~~ 
,V,' ,~ ", I.~t~~, AH~~'~r, AH AH ~I " 
HB ~: ,...tv.;."1 ~\, l : r'\ 
I...J • L..J - I.j ., "t Of OfJ 
episodes of tachycardia were terminated with adenosine (Fig. 
3). On both occasions, block occurred in the retrograde limb 
of the tachycardia circuit. In the other patient (Case 9), 
adenosine, up to a dose of 450 JLg/kg, produced no effect 
on the tachycardia. This patient had been receiving a sus-
tained release theophylline preparation and had a theo-
phylline plasma concentration of 19.4 JLg/ml (l X 10 - 4 
M) at the time of study. 
IntraatriaI reentrant tachycardia. Six patients (Cases 
32 to 37) in this series demonstrated supraventricular tachy-
cardia due to intraatrial reentry. Atrial cycle lengths during 
tachycardia in the absence of antiarrhythmic drugs ranged 
from 250 to 380 seconds (319 ± 36). Adenosine admin-
istration did not terminate any of these arrhythmias and did 
not affect atrial cycle length. In each case, however, second 
degree A V block within the A V node could be induced by 
adenosine administration at a mean dose of 127 ± 65 JLg/kg 
(9.4 ± 7 mg). Second degree A V block occurred 23 ± 10 
seconds after injection. In several patients whose P wave 
configuration was indistinct on the surface electrocardio-
gram, adenosine-induced A V block allowed clear visual-
ization of atrial activity as well as differentiation between 
the P wave during tachycardia and that during normal sinus 
rhythm. 
Other arrhythmias. One patient (Case 38) with sinus 
node reentrant tachycardia was studied. In this patient, aden-
Figure 4. Case 38. Effect of aden-
osine on sinus node reentrant 
tachycardia. The tracings are la-
beled as in Figures 1 and 2. Aden-
osine (37.5 IJ-g/kg) injected 17 sec-
onds before the start of the tracing 
produces transient second degree 
A V nodal block. In this case, atrial 
activation and P wave configura-
tion were identical to those ob-
served during sinus rhythm. 
f--I sec----i 
osine at a dose of 37.5 JLg/kg (3.4 mg) produced 2: I AV 
block (Fig. 4). The next higher dose of 75 JLg/kg produced 
a higher grade block. The atrial activation sequence and 
cycle length did not change. Increased doses could not be 
given to this patient because dyspnea occurred with admin-
istration of the larger dose. 
High grade A V block without alteration of the pattern of 
atrial activity was also produced by adenosine injection in 
four patients with atrial flutter (Cases 5 to 8), in one patient 
with automatic atrial tachycardia (Case 1) and in three pa-
tients with atrial fibrillation (Cases 2 to 4). No effect on 
atrial activity was observed in these eight patients. As shown 
in Figure 5, the higher grade A V block seen transiently after 
adenosine injection frequently facilitated analysis of the 
mechanism of the arrhythmia from the surface electro-
cardiogram. 
Adverse etTects. Nine (20%) of 46 patients reported 
transient dyspnea at the time when their arrhythmia was 
broken by adenosine. Seven (15%) also reported flushing. 
All of these symptoms were described as minor and lasted 
only a few seconds. In two patients who received adenosine 
during supraventricular tachycardia at doses of the nucleo-
side higher than those required to produce either tachycardia 
/ 
termination or A V block, atrial trutter or fibrillation was 
observed. In both of these patients, the new arrhythmia 
lasted less than I minute. None of the 11 patients studied 
I-I sec-I 
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Figure 5. Case 8. Effect of adenosine on atrial flutter. The clinical 
diagnosis made in the emergency room was A V nodal reentrant 
tachycardia because atrial activity could not be defined on the initial 
electrocardiogram. The patient received adenosine and the correct 
diagnosis of atrial flutter was then made. The tracings shown here 
were obtained during a second adenosine trial after a pacing cath-
eter had been positioned in the high right atrium (HRA) in an 
attempt to terminate th~ arrhythmia with rapid atrial pacing. Ab-
breviations as in Figure I. 
during a spontaneous clinical episode of arrhythmia devel-
oped a second atrial tachyarrhythmia after adenosine. 
Three patients with recurrent supraventricular tachycar-
dia also had clinically manifested sinus node dysfunction. 
When tl1eir previously inserted ventricular demand pace-
maker was inhibited or reprogrammed to the slowest pos-
sible rate, periods of 2 to 5 seconds of sinus arrest were 
observed after termination of the supraventricular tachy-
cardia episode by adenosine. These pauses were similar to 
those observed in the same patients after atrial pacing during 
measurement of the sinus node recovery time or after supra-
ventricular tachycardia termination with atrial burst pacing. 
In all the other patients, sinus rhythm resumed promptly 
after termination of supraventricular tachycardia. 
Drug interactions. Patients who received adenosine at 
the time of e1ectrophysiologic study had their previous an-
tiarrhythmic therapy terminated. However, patients studied 
during clinical episodes of arrhythmia were frequently tak-
ing antiarrhythmic drugs, and some patients received an 
antiarrhythmic drug during the course of electrophysiologic 
study and then received a subsequent adenosine trial if 
supraventricular tachycardia could be reinitiated. In the en-
tire series, 11 patients had received therapeutic doses of 
digoxin, 3 of verapamil, 1 of propranolol, 3 of quinidine, 
I of disopyramide and I of amiodarone before at least one 
JACC Vol. 6. No.2 
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administration of adenosine. No adverse interactions were 
noted. Only six patients received adenosine at their elec-
trophysiologic study both before and after administration of 
a second drug. Although we did not observe any change in 
the dosage of adenosine required for effect in these patients, 
this number is too small to exclude any possibility of syn-
ergistic or antagonistic drug interactions. Four patients re-
ceived atropine (0.02 or 0.03 mg/kg) before at least one 
adenosine trial. Atropine did not affect the response to aden-
osine. One patient (Case 9), as described previously, was 
receiving sustained release theophylline. She had no elec-
trophysiologic response after doses of adenosine up to and 
including 450 jLg/kg. 
Discussion 
Therapeutic efficacy. Our data indicate that in humans, 
adenosine administration provides a rapid and effective method 
for terminating individual episodes of supraventricular 
tachycardia whenever intact A V nodal conduction is a re-
quired part of the reentrant circuit. Tachycardia termination 
was produced during the first pass of the injected adenosine 
boll1s through the heart. The duration of the adenosine effect 
was brief and neither unanticipated sinus node depression 
nor arterial hypotension was observed after termination of 
the tachycardia. Patients in this series whose arrhythmias 
did not require intact A V nodal conduction for their con-
tinuation manifested only increased A V block in response 
to adenosine. 
Dosage requiremen~s. In this study we determined the 
minimal effective dose for each patient. There was a 7-fold 
range of effective doses when calculated on the basis of 
milligrams of adenosine per kilogram body weight and a 
lO-fold range when only the number of milligrams required 
was considered. Several factors may account for these ob-
servations. Because adenosine begins to be cleared from the 
circulation immediately after injection and plasma clearance 
is complete in less than a minute, the speed of injection, 
the circulation time from the site of injection to the heart 
and the central volume in which the bolus mixes will all 
affect the concentration of adenosine that reaches the cardiac 
adenosine receptor. The effects of each of these variables 
on the concentration of adenosine that reached the heart in 
each patient could not be determined. We did not attempt 
to measure adenosine concentrations in plasma because this 
rapid clearance of adenosine from plasma would continue 
during withdrawal of the sample unless an adenosine uptake 
inhibitor had previously been administered. Although the 
electrophysiologic action of adenosine is not dependent on 
muscarinic or adrenergic receptors, another factor that might 
account for the wide range of effective doses is the level of 
adrenergic or vagal tone that might noncompetitively an-
tagonize or enhance the effects of adenosine. For these 
reasons, wide interindividual dosage requirements were not 
JACC Vol. 6, No.2 
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unexpected and this variability of response makes prediction 
of a uniform optimal dose for all patients difficult. However, 
in patients who received the drug more than once, the dose 
required for arrhythmia termination was relatively constant 
for each patient at any point in time. 
The need to individualize dosage for each patient is an 
important factor that must be considered before adenosine 
is widely used clinically. Overdosage might lead to pro-
longed asystole, hypotension or other tachyarrhythmias. Even 
though the direct effects of adenosine are quite brief, their 
duration seems to be proportional to the dose in each patient 
and these side effects could be serious in certain patients. 
However, when we used gradually increasing doses and 
administered only the minimal effective dose for each pa-
tient, no serious cardiac side effects were observed in well 
over 100 trials in the 46 patients reported here, In clinical 
practice, the rapid uptake and metabolism of adenosine would 
permit the physician to individualize the dose for each pa-
tient by simply starting with a relatively low dose of ap-
proximately 30 to 40 jLg/kg for peripheral injection and then 
increasing the dose at I minute intervals until the desired 
effect was produced. Lower doses should be used for central 
administration due to the decreased circulation time before 
the bolus reaches the heart. We estimate that almost all 
episodes of supraventricular tachycardia could be effectively 
managed in this fashion within 5 minutes of the first aden-
osine injection. 
Although the rapid uptake and metabolism of adenosine 
allow easy dose titration, they also limit the potential use-
fulness of the drug, All trials reported in this study involved 
intravenous administration of a single bolus, It is unlikely 
that either an oral or intramuscular route of administration 
would prove effective. In addition, the brief duration of 
action of adenosine makes it unlikely that the compound 
itself would be useful for chronic prophylaxis or for the 
control of ventricular rates in rhythms originating above the 
A V node, The development of longer-acting adenosine an-
alogs might permit chronic therapy, but unless an analog 
specific for the A V nodal adenosine receptor is developed, 
the chronic adenosine-like activity of the analog in the many 
organs in which adenosine plays an important physiologic 
role would have to be considered. 
Comparison with other agents. The use of intravenous 
verapamil and other calcium antagonists for the acute ther-
apy of supraventricular tachycardia has largely replaced the 
use of digitalis, propranolol, edrophonium, vasoconstrictor 
agents and cardioversion ( 13). Verapamil has a high success 
rate and is usually well tolerated. However, verapamil may 
produce systemic hypotension and depress ventricular con-
tractility. Should these side effects occur, they may persist 
for minutes or hours until the drug is cleared from the 
circulation. 
Our series is not the first to use a purinergic compound 
for treating atrial arrhythmias. An injectable preparation of 
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adenosine triphosphate (A TP) is available in some European 
countries and is under investigation in the United States for 
the therapy of supraventricular tachycardia (Striadyne, Lab-
oratories Auclair; ATP-Ormonoterapia, Richter). It was 
originally postulated that A TP terminated supraventricular 
tachycardia by delivering a "high energy shock" to the 
heart (14). Recent studies in our laboratory (15) have dem-
onstrated that the significant components of the actions of 
ATP are produced in most species, including humans, after 
its conversion to adenosine. The studies describing the ef-
ficacy of intravenous A TP for terminating supraventricular 
tachycardia have all employed relatively fixed doses of the 
drug (6,16-20). In contrast, we used gradually increasing 
doses of adenosine to achieve maximal efficacy with min-
imal toxicity and observed that a wide range of doses was 
required. In this study, all arrhythmia episodes that required 
intact A V nodal conduction with one exception were ter-
minated with only minor side effects. We anticipate that a 
similar protocol for dosage adjustment that employed ATP 
rather than adenosine would produce the same results. Even 
with these reservations, the use of ATP has compared quite 
favorably with the use of digoxin or verapamil for treating 
supraventricular tachycardia (19). 
Contraindications. The advantage of the very short du-
ration of action of adenosine should not be considered ap-
plicable to patients who were receiving an agent (for ex-
ample, dipyridamole) that markedly affects adenosine 
metabolism. At present we cannot give dosage guidance for 
use in such patients. 
Our data suggest that there would be few other con-
traindications to the use of adenosine in patients with supra-
ventricular tachycardia. Long sinus node pauses were ob-
served in patients with previously documented sinus node 
dysfunction, but these were also noted when other modes 
of arrhythmia termination were employed. Atrial flutter or 
fibrillation was only noted when doses higher than necessary 
for supraventricular tachycardia termination or A V block 
were used. Nevertheless, caution should be exercised when 
adenosine is used in patients capable of rapid A V conduc-
tion. The only common adverse reactions, dyspnea and 
flushing, which were reported by one-third of the patients, 
were very mild and lasted only a few seconds. These side 
effects are presumably due to the direct actions of adenosine 
as a weak bronchoconstrictor (21) and cutaneous vasodilator 
(22). 
Diagnostic uses. In addition to its potential use for treat-
ing individual episodes of supraventricular tachycardia that 
involve the A V node, adenosine administration may facil-
itate the diagnosis in patients with other mechanisms of 
arrhythmia. On the basis of in vitro data (2), we postulate 
that arrhythmias due to some types of triggered automaticity 
should also respond, although no patient with such an ar-
rhythmia was available for inclusion in this series. In pa-
tients with a supraventricular arrhythmia that does not re-
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quire A V nodal conduction, adenosine will not produce 
arrhythmia termination, but the high grade A V nodal block 
that it causes will allow a clear demonstration of atrial ac-
tivity. This may prove useful as a diagnostic maneuver in 
some patients with intraatrial reentry, atrial flutter or fi-
brillation and those with multiple accessory pathways. 
Although we were able to assess the effects of adenosine 
in only single patients with sinus node reentrant tachycardia, 
junctional tachycardia with a long RP interval or automatic 
atrial tachycardia, the results obtained may offer insights 
into the mechanisms of these arrhythmias. Adenosine has 
marked effects on sinus node automaticity at the same con-
centrations in humans which affect A V nodal conduction 
(9). In our patient with sinus node reentrant tachycardia, 
adenosine did not affect atrial activity but did produce A V 
block. This finding suggests that the conduction abnormality 
responsible for sinus node reentry either is within the node 
itself but has a different response from sinus node auto-
maticity to adenosine, or that the arrhythmia in this patient 
arose at the sinoatrial junction. 
The results in the patient with junctional reciprocating 
tachycardia with a long RP interval are of interest. This 
arrhythmia has been postulated to involve anterograde con-
duction over the A V node and retrograde conduction over 
an accessory A V node, a slow dual A V nodal pathway or, 
as recently demonstrated, a septal accessory pathway with 
decremental conduction (23-26). Adenosine interrupted the 
tachycardia in our patient during retrograde conduction. This 
would suggest that accessory pathways with decremental 
conduction, unlike those in our other patients, are sensitive 
to adenosine. The recent report by Perrot et al. (27) that 
some accessory pathways with long anterograde refractory 
periods are sensitive to adenosine triphosphate supports this 
hypothesis. 
Atrial activity in our patient with automatic atrial tachy-
cardia was also unaffected by adenosine administration. This 
patient had cardiac metastases from a mediastinal carci-
noma. We postulated that his arrhythmia was caused by 
local invasion of the atrium and our results suggest that 
increased automaticity in this setting is not sensitive to 
adenosine. 
Conclusions. It has only been recently recognized that 
adenosine may have an important role as an endogenous 
local regulator of cardiac electrophysiology. The data pre-
sented here indicate that an appreciation of the electro-
physiologic properties of adenosine may permit more ef-
fective diagnostic evaluation and therapy of patients with 
supraventricular arrhythmias. Adenosine has a predictable 
onset of action, is highly effective in arrhythmias that require 
A V nodal conduction and has only minor toxicity. The use 
of adenosine in the acute treatment of supraventricular 
tachycardia represents an effective alternative to the present 
modes of therapy. 
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